Operating Margin for Clovis Oncology (CLVS)

Operating Margin as of March 2025 (TTM): -163.43%

According to Clovis Oncology's latest financial reports and stock price the company's current Operating Margin is -163.43%. At the end of 2021 the company had an Operating Margin of -178.09%.

Operating Margin history for Clovis Oncology from 2017 to 2022

Operating Margin at the end of each year

Year	Operating Margin	Change
2021	-178.09%	-20.76%
2020	-224.75%	-19.37%
2019	-278.75%	-27.63%
2018	-385.16%	-38.91%
2017	-630.46%	-99.87%
2016	-488,680.77%
2014	-1,157.60%

Operating Margin for similar companies or competitors

Company	Operating Margin	Operating Margin differencediff.	Country
BioMarin Pharmaceutical BMRN	18.98%	-111.61%	🇺🇸 USA
AstraZeneca AZN	16.07%	-109.83%	🇬🇧 UK
Pfizer PFE	12.60%	-107.71%	🇺🇸 USA
Johnson & Johnson JNJ	18.78%	-111.49%	🇺🇸 USA
AbbVie ABBV	6.59%	-104.03%	🇺🇸 USA
Eli Lilly LLY	28.15%	-117.22%	🇺🇸 USA

What is a company's Operating Margin?

The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.

What is the market capitalization of a company?

The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company.
In most cases it can be easily calculated by multiplying the share price with the amount of outstanding shares.

DISCLAIMER

CompaniesMarketCap is not associated in any way with CoinMarketCap.com
Stock prices are delayed, the delay can range from a few minutes to several hours.
Company logos are from the CompaniesLogo.com logo database and belong to their respective copyright holders. Companies Marketcap displays them for editorial purposes only.

Contact

For inquiries or if you want to report a problem write to hello@8marketcap.com

Links

- Privacy policy

- Terms and conditions